key: cord-0774990-j0bu0upi
authors: Salazar, Eric; Christensen, Paul A.; Graviss, Edward A.; Nguyen, Duc T.; Castillo, Brian; Chen, Jian; Lopez, Bevin Valdez; Eagar, Todd N.; Yi, Xin; Zhao, Picheng; Rogers, John; Shehabeldin, Ahmed; Joseph, David; Leveque, Christopher; Olsen, Randall J.; Bernard, David W.; Gollihar, Jimmy; Musser, James M.
title: Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
date: 2020-08-11
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2020.08.001
sha: e5cfc69ec7025b0ce9f3ccce9fab8d4330a0c84e
doc_id: 774990
cord_uid: j0bu0upi

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and proven treatments are limited. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 is among many approaches being studied as potentially efficacious therapy. We are conducting a prospective, propensity score-matched study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for severe and/or critical COVID-19. We present here the results of an interim analysis of 316 patients (n=316) enrolled at Houston Methodist hospitals from March 28 to July 6, 2020. Of the 316 transfused patients, 136 met a 28-day outcome and were matched to 251 non-transfused control COVID-19 patients. Matching criteria included age, sex, BMI, comorbidities, and baseline ventilation requirement 48 h from admission, and in a second matching analysis, ventilation status at Day 0. Variability in the timing of transfusion relative to admission and titer of antibodies of plasma transfused allowed for analysis in specific matched cohorts. The analysis showed a significant reduction (P = 0.047) in mortality within 28 days, specifically in patients transfused within 72 h of admission with plasma with an anti-spike protein receptor binding domain titer of ≥1:1350. These data suggest that treatment of COVID-19 with high anti-receptor binding domain (RBD) IgG titer convalescent plasma is efficacious in early-disease patients.

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally and cause massive societal disruption and death. As of August 3, 2020, COVID-19 has been responsible for more than 18 million cases and approximately 690,000 deaths worldwide https://coronavirus.jhu.edu/map.html. The United States is in the midst of a substantial surge of new cases, and despite months of effort, very few treatment options with proven efficacy for COVID-19 are available. Currently, hundreds of registered clinical trials are underway, the majority of which are assessing antiretroviral agents, anti-inflammatory or immunosuppressant therapies, and passive antibody treatments. [1] [2] [3] The antiretroviral Remdesivir, an RNA polymerase inhibitor with activity against SARS-CoV and MERS-CoV, 4 has shown promise in a recent randomized controlled trial, 5 reducing recovery time in certain COVID-19 patients. In addition, dexamethasone was recently shown to reduce mortality in patients receiving oxygen, including mechanically ventilated patients. 6 Many vaccines are in various stages of development and one is being studied in a phase 3 trial, 7 but it will be at least many months before an efficacious vaccine is available. 8, 9 Thus, although many prophylactic and therapeutic strategies are under investigation, the primary management of COVID-19 disease remains supportive care.

Convalescent plasma therapy has been used to treat patients during previous coronavirus outbreaks, [10] [11] [12] [13] the 2009 H1N1 epidemic, 14 and the Ebola outbreak. 15 Thus, early in the current pandemic, convalescent plasma therapy was proposed as a potential therapeutic and prophylactic option 16 . The Food and Drug Administration (FDA) rapidly made pathways available for the administration or study of COVID-19 convalescent plasma, and convalescent plasma remains the only widely available passive antibody therapy. Under the federally supported expanded access program coordinated by Mayo Clinic, as of July 11, 2020, more than 34,000 patients have been transfused with convalescent plasma https://www.uscovidplasma.org, with minimal adverse events. 17 We and others have shown similar safety findings. [18] [19] [20] [21] [22] [23] J o u r n a l P r e -p r o o f

We recently published our early experience with convalescent plasma treatment in 25 patients with severe COVID-19 disease. 19 By Day 14 post-transfusion, 19 patients (76%) had improved or been discharged. 19 However, conclusions regarding efficacy were hindered by lack of a control group, administration of concomitant antiretroviral and immunosuppressant therapies, non-standardization of anti-SARS-CoV-2 antibodies in donated plasma, and variation in disease severity at baseline (day of transfusion) in the plasma recipients.

To further investigate our initial observations, we are conducting a prospective, propensity score-matched study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for severe and/or critical COVID-19 disease. The study is ongoing, with 316 patients transfused to date. Herein, we report results of an interim analysis. The data suggest that transfusion of high anti-spike protein receptor binding domain (RBD) IgG titer convalescent plasma early in hospital admission reduces mortality by 28 days post-transfusion.

This prospective, ongoing study analyzed data from the eight Houston Methodist hospitals from March 28, 2020, through July 6, 2020, with the approval of the Houston Methodist Research Institute ethics review board and with informed patient or legally-authorized representative consent. Patients were treated under an investigational new drug (IND) application approved by the FDA https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policyframework/emergency-use-authorization. Approval to treat the first patient was granted on April 3, 2020. Four patients treated under an emergency investigational new drug (eIND) application were approved between March 28, 2020 and April 3, 2020, and were also included in the analysis.

COVID-19 patients admitted to any of the eight Houston Methodist hospitals were considered for enrollment in this trial. SARS-CoV-2 infection was diagnosed by RT-PCR test, as described J o u r n a l P r e -p r o o f previously. 19, 24, 25 Patients were eligible for this study if they had severe and/or life-threatening COVID-19 disease https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigationalcovid-19-convalescent-plasma. Severe disease was defined as one or more of the following: shortness of breath (dyspnea), respiratory rate ≥ 30/min, blood oxygen saturation ≤ 93% (on room air), partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or pulmonary infiltrates > 50% within 24 to 48 h (of screening assessment). Life-threatening disease was defined as one or more of the following: respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Patient recruitment early in the study involved investigators reaching out to treatment teams and patients. As the pandemic progressed in the Houston metropolitan region and awareness regarding convalescent plasma as a treatment option increased, recruitment into the study transitioned to the study investigators screening requests for enrollment of patients from treatment teams across the hospital system. Fewer patients with very advanced disease (intubated/on ECMO) were enrolled later in the study. Patients were excluded if: there was a history of prior severe reactions to transfusion of blood products with imputability of probable or definite, as defined by the CDC NHSN Hemovigilance Module 26 ; they had underlying uncompensated and untreated end-stage disease; and/or patients had fluid overload or other condition that would contraindicate administration of plasma.

Patients were transfused with one or two units of COVID-19 convalescent plasma. Criteria for a second transfusion included, but were not limited to: worsening imaging findings (X-ray/CT) thought to be due to COVID-19; increasing oxygenation requirement thought to be due to COVID-19; worsening PaO2/FiO2 ratio thought to be due to COVID-19; worsening hemodynamic status thought be due to  or new end-organ failure thought to be due to COVID-19; or BMI >30 kg/m 2 . As plasma inventory was limited early in the study, a second unit was not always available. Transfusion of a second unit was also influenced by patient enrollment in other trials that prohibited additional doses of convalescent plasma.

Our protocols for convalescent plasma collection have been described. 19, 25 Briefly, convalescent plasma was obtained by apheresis and processed by standard blood banking protocols under Houston J o u r n a l P r e -p r o o f Methodist human subjects protocol PRO00025121. FDA recommendations for COVID-19 convalescent plasma donor collection were followed https://www.fda.gov/vaccines-blood-biologics/investigationalnew-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19convalescent-plasma#Patient%20Eligibility. Each donor had recovered from laboratory-confirmed SARS-CoV-2 infection based on a positive RT-PCR test. All plasma was donated by recovered and healthy COVID-19 patients who had been asymptomatic for more than 14 days. Donors were between 18-65 years, and all provided written informed consent and tested negative for SARS-CoV-2 at the time of plasmapheresis. If eligible according to standard blood donor criteria, donors were enrolled in a frequent plasmapheresis program. Donors were documented to be negative for anti-HLA antibodies, hepatitis B, hepatitis C, HIV, HTLV I/II, Chagas disease, WNV, Zika virus, and syphilis, per standard blood banking practices.

Convalescent plasma titer assessment was performed as recently described. 19, 25 Briefly, purified recombinant ectodomain (ECD), comprised of amino acid residues 1-1208, and/or RBD, comprised of amino acids 319-591, of the SARS-CoV-2 spike protein (GenBank MN908947 https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3) were coated onto microtiter plates. Human monoclonal antibody CR3022 that targets the RBD of SARS-CoV was used as a positive control. 27 Negative serum control was included on each microtiter plate. Serial dilutions of serum were added, incubated for 1 h, washed, incubated with goat anti-human IgG Fab HRP (Sigma A0293), and washed.

ELISA substrate (1-step Ultra TMB, Thermo Scientific cat# 34028) was added, plates were developed until the highest dilution reached the saturation point, and the reaction was stopped with H 2 SO 4 . Plates were read at an absorbance of 450 nm.

Patient characteristics and outcomes were reported as frequencies and proportions for categorical variables, and median and interquartile range (IQR) or mean and standard deviation (SD) for continuous variables, as appropriate. Differences between groups (e.g., transfused versus non-J o u r n a l P r e -p r o o f transfused) were determined by the Wilcoxon rank-sum test or t-test for continuous variables, and Chisquare or Fisher's exact tests for categorical variables as appropriate.

Only patients who met a 28-day outcome, defined as having outcome data available 28 days post-transfusion (cases) and 28 days post-admission (controls), were analyzed. Patients discharged before Day 28 were presumed to be on room air after discharge, unless otherwise noted in the electronic health record. Baseline patient characteristics for all COVID-19 patients and for patients who met a 28-day outcome are shown in Supplemental Table S1 .

We conducted a one-to-many nearest neighbor propensity score matching without replacement using an initial ratio of case:control = 1:3 and caliper of 1 between patients having plasma transfusion (cases) versus patients who did not have plasma transfusion (controls). The primary matching criteria included age (categorical, <30, 30-39, 40-49, 50-59, 60-69, 70-79, ≥80), sex, BMI (</>=30), diabetes, hypertension, chronic pulmonary disease, chronic kidney disease, hyperlipidemia, coronary disease, and baseline ventilation requirement within 48 h from admission. A secondary propensity score matching the ratio of case:control of either 1:2 or 1:1 and caliper <1 was conducted based on the ventilation status at Day 0, which was defined as the day of transfusion for cases and the corresponding day in the hospitalization course for controls 28 Table S2 ).

Variability in the timing of transfusion and the titer of plasma allowed for analysis in specific matched cohorts. The following pre-specified sub-groups of transfused patients were also identified and matched with available controls: patients transfused with plasma within 72 h of admission; patients who were transfused >72 h after admission; and patients transfused within 72 h of admission with an anti-RBD IgG titer ≥1:1350 ( Table 1) . A titer of ≥1:1350 was chosen based on our previous work that demonstrated that an anti-RBD IgG 1:1350 indicated an 80% probability of viral neutralization titer ≥1:160, the recommended viral neutralization cutoff for COVID-19 convalescent plasma for therapeutic purposes. 25 Cohort-specific propensity score matching runs were executed for individual cohorts (e.g., plasma with all anti-RBD IgG titers, titer ≥1:1350, titer<1:1350, etc.) to ensure that a balance of all matching criteria was kept within the individual cohorts. The cohort-specific secondary propensity score J o u r n a l P r e -p r o o f matches started with case:control ratio of 1:2 to maximize precision. The case:control ratio decreased to 1:1 for some cohorts when there were not enough matched controls available. We also conducted a sub-analysis comparing outcomes in subgroups of transfused patients to each other rather than to matched controls. One subgroup was added based on post-hoc assessment of the matched data: patients transfused after 72 h of admission with plasma with an anti-RBD titer <1:1350.

The primary outcome, mortality within 28 days post-Day 0, is depicted by the Kaplan-Meier curves. Differences between groups were compared using the log-rank test. Cox proportional hazards modeling (with clustered sandwich estimator option for the matched cluster in the propensity matched cohorts) was performed to determine the characteristics associated with the overall mortality within 28 days. Variables for the multivariable models were selected based on potential clinical relevance and also by the Stata's Lasso technique with the cross-validation (CV) selection option 29, 30 . 

We had 2,724 admitted COVID-19 patients available for analysis, 316 of whom were transfused with COVID-19 convalescent plasma (Figure 1) . Baseline characteristics of all admitted COVID-19 patients are shown in Supplemental Table S1 . Relative to non-transfused patients, transfused patients generally were younger, predominantly male, had a higher BMI, lower rates of comorbidities (specifically, chronic pulmonary disease, chronic kidney disease, hyperlipidemia, coronary disease, and hypertension, but not diabetes), a higher requirement for supplemental oxygen, and higher inflammatory marker concentrations. Use of steroids, azithromycin, and tocilizumab was more common among the transfused cohort, but use of Remdesivir was not. The majority of transfused patients Initial propensity score matching yielded a study population of 145 transfused patients and 435 matched controls. This primary propensity score matching, including requirement for supplemental oxygen or mechanical ventilation within 48 h of admission, yielded a significant difference between the case and control cohort with respect to ventilation status at Day 0: 35% of controls were on room air at Day 0 compared to only 9% of cases. Table 1 and Supplemental Table S2 present the baseline characteristics of cohorts after secondary matching for ventilation status at Day 0, which were balanced in all matching criteria. After this secondary matching, there were 136 transfused patients matched to 251 controls (Figure 1 ).

Outcomes A decreased probability of death within 28 days post-Day 0 was observed in the transfused cohort relative to propensity score-matched controls, although the difference did not reach statistical significance (Figure 2A) . We hypothesized that transfusion early in hospitalization is more beneficial than transfusion later. Consistent with the hypothesis, relative to matched controls, patients transfused within 72 h of hospital admission had decreased mortality within 28 days, whereas patients transfused after 72 h of hospital admission did not. The decreased mortality was improved and reached significance (P = 0.047) when only patients who received a plasma transfusion with an anti-RBD IgG titer of ≥1:1350 (high titer) within 72 h of hospital admission were considered (Figure 2 , B, C, and D).

Point estimates of the various outcomes confirm these findings ( Table 2) 

In propensity score-matched patients, univariate analysis indicated that factors associated with higher mortality were advanced age, hypertension, diabetes, chronic kidney disease, coronary disease, higher interleukin-6, higher d-dimer, and use of any steroid, ribavirin, or tocilizumab. Multivariate analysis, in a model excluding variables that were used in the propensity score match, showed that the risk of mortality within 28 d was increased in patients who were not transfused with convalescent plasma (regardless of titer or timing), with a trend toward significance [(adjusted hazard ratio (HR) 2.73 (95% CI 1, 7.48), P = 0.051] (Supplemental Tables S5 and S6 ). Multivariate analysis is not yet possible with the various sub-analysis cohorts, including those patients transfused with high titer plasma within 72 h of admission, due to low number of events (deaths), overall.

Tens of thousands of COVID-19 patients in the United States have now been transfused with convalescent plasma. This treatment has been documented to be safe; however, few controlled studies that assess efficacy have been published. Here, we provide the results of interim analysis of a prospective, ongoing matched study. In aggregate, the data suggest that transfusion of high anti-RBD J o u r n a l P r e -p r o o f IgG titer convalescent plasma early in the hospital course significantly reduces mortality. Several lines of evidence support our conclusion, including survival analysis of specific cohorts of transfused patients relative to matched controls, point estimates from GLM and multinomial logistic regression, multivariate analysis, and comparisons of outcomes in different cohorts of transfused patients.

Our results are also consistent with previous studies. 28, 31-34 A recent randomized clinical trial of 101 cases and controls examined clinical improvement up to 28 d post-transfusion, and found that 52% of plasma recipients had improvement versus 43.1% of the control group. 34 Although no significant difference in 28-day mortality was observed, the conclusions were limited by early termination of the study due to low enrollment as the regional outbreak waned. 34 A second study examined efficacy in 39 patients compared to retrospectively matched controls. 28 The results showed that patients receiving convalescent plasma therapy had improved survival and supplementary oxygen requirements at Day 14 post-transfusion compared to non-transfused controls. In a smaller study by Hegerova et al., 20 COVID-19 patients who received convalescent plasma had improved laboratory and respiratory parameters compared to matched controls, and in both matched control studies, non-intubated patients benefited more from transfusion than intubated patients. 28, 33 Very early in the pandemic, convalescent plasma was administered under emergency use protocols without knowledge of donor plasma antibody or virus neutralization (VN) titers. For donor plasma, the FDA has recommended a VN titer of at least 1:160 https://www.fda.gov/vaccines-bloodbiologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendationsinvestigational-covid-19-convalescent-plasma#Patient%20Eligibility. We recently demonstrated that the probability of having a VN titer ≥160 was >80% with plasma anti-RBD or anti-ectodomain titers of ≥1:1350. 25 Thus, when we generated these data, and as our pool of high titer donors grew, we changed to transfusing only plasma with at least this titer of anti-RBD IgG. This evolving approach permitted us to retrospectively compare outcomes in different cohorts of patients with respect to the titer anti-RBD IgG of plasma received. Our finding that high anti-RBD IgG titer plasma is more efficacious is consistent with work showing that the RBD of the spike protein is the important region for ACE2 Table 2 ) may indicate that the risk/benefit ratio of convalescent plasma is different later in the course of the disease.

Our analysis has implications for collection, use, and study of COVID-19 convalescent plasma.

In our experience, many requests for convalescent plasma are for patients who have already received other therapies and are late in their disease course. Although in the aggregate convalescent plasma is a safe therapy, our data argue that careful consideration should be given to the potential risks and benefits given the clinical context, as transfusion may only be beneficial early in the clinical course.

Substantial efforts are underway in the US to collect COVID-19 convalescent plasma. Our data indicate that assessment of antibody titer through a viral neutralization assay or a surrogate thereof is likely to identify donors and plasma units that are most likely to be beneficial. Clinical trials are ongoing in many J o u r n a l P r e -p r o o f centers, and the data presented here may inform the assessment of equipoise in their design and conduct. [39] [40] [41] [42] Our study has several limitations. First, although the patient sample size is large, it is an interim analysis of an ongoing study. Second, it is not a randomized, controlled trial, but rather a propensity score-matched analysis. Although we made every effort to control for important covariates, it is not yet possible to match for all potentially relevant covariates, given the sample sizes. Because race, ethnicity, inflammatory markers, ABO type, and concomitant medications were not included in the match parameters, there were statistically significant differences in these characteristics among the various cohorts. The background standard of care for COVID-19 is evolving as new data emerge. In our matched cohort of patients transfused with high-titer plasma within 72 h of admission, there were significant differences in the use of prednisone (higher in non-transfused), hydroxychloroquine (higher in non-transfused), ribavirin (higher in non-transfused), and tocilizumab (higher in transfused). Thus, we

have not yet completely addressed the potential for variations in background standard of care and period effect as sources of confounding in our dataset, although it is important to note that we did not observe a significant difference in the distribution of date of death over the study period between overall secondary-matched cases and controls. As our population of cases and controls that meet a 28-day outcome increases, additional matching approaches may be included, and these may impact future findings. Third, the strict matching criteria we used resulted in small sample sizes in the sub-analyses, prohibiting multivariate analysis. Fourth, there was heterogeneity in the administration of two transfusions versus one based on inventory limitations early in the study and on patient enrollment in other trials that excluded redosing of convalescent plasma. Fifth, we did not exclude non-transfused control patients if they were enrolled in other clinical trials. This is likely to be a small minority of control patients, as all clinical trials for COVID-19 therapies in our system, other than convalescent plasma, were only offered at our flagship hospital in the Texas Medical Center. Access to these enrollment lists in the future will allow for such exclusion. Sixth, this interim analysis was based on data available in the electronic health record. Finally, the results reflect the experience of a system of eight hospitals in the J o u r n a l P r e -p r o o f Houston metropolitan region and may not be applicable to all centers. However, we note that our hospital system serves a metropolitan region with a highly diverse population of 7 million people.

In conclusion, this interim propensity score-matched analysis suggests that transfusion of high anti-RBD IgG titer COVID-19 convalescent plasma early in hospitalization reduces mortality in COVID-19 patients. 

≥80 3 (1.3) 3 (2.7) 0 (0.0) 1 (1.1) 0 (0.0) 1 (3.2) 2 (0.8) 2 (1.3) 0 (0.0) Sex1 (0.9) 0 (0.0) -- -- 0 (0.0) 0 (0.0) 0 (0.0) -- -- 2 (0.8) 2 (1.3) 0 (0.0) -- -- High flow/NIPPV 0 (0.0) 0 (0.0) 0 (0.0) -- -- 0 (0.0) 0 (0.0) 0 (0.0) -- -- 0 (0.0) 0 (0.0) 0 (0.0) 0

Review of trials currently testing treatment and prevention of COVID-19

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

A Phase III study to investigate a vaccine against COVID-19

SARS-CoV-2 Vaccines: Status Report. Immunity 2020

The SARS-CoV-2 Vaccine Pipeline: an Overview

Use of convalescent plasma therapy in SARS patients in Hong Kong

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Alahmadi M: Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

The convalescent sera option for containing COVID-19

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Patients with Convalescent Plasma

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Treatment with convalescent plasma for COVID-19 patients in Wuhan

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients

Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma

USCfDCa: The National Healthcare Safety Network (NHSN) Manual: Biovigilance Component v2

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Convalescent plasma treatment of severe COVID-19: A matched control study

Statistical Learning with Sparsity: The Lasso and Generalizations

Lasso SS: Stata Reference Manual: Release 16

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

Convalescent Plasma for COVID-19. A randomized clinical trial

Pagel JM: Use of Convalescent Plasma in Hospitalized Patients with Covid-19 -Case Series

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Passive antibody therapy for infectious diseases

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Convalescent Plasma Study G: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection

The Serum Treatment of Lobar Pneumonia

Remarks on THE SERUM TREATMENT OF PNEUMONIA